BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Pravastatin or Atorvastatin Evaluation and Infection Therapy (TIMI22)

Phase 4

Completed

Conditions: Actue Coronary Syndromes

First Posted Date: 2006-09-29

Last Posted Date: 2011-04-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 4000

Registration Number: NCT00382460

A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug

Completed

Conditions: Liver Diseases

Interventions: Drug: Dasatinib

First Posted Date: 2006-09-29

Last Posted Date: 2011-04-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 40

Registration Number: NCT00382668

Locations: 🇺🇸
University Of Miami, Miami, Florida, United States
🇺🇸
New Orleans Center For Clinical Research, Knoxville, Tennessee, United States
🇺🇸
Comprehensive Phase One, Miramar, Florida, United States

and more 1 locations

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Metastasis

Interventions: Drug: Dasatinib
Drug: Dasatinib 100 mg

First Posted Date: 2006-09-04

Last Posted Date: 2011-04-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 92

Registration Number: NCT00371345

Locations: 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸
Ucsf-Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States

and more 5 locations

A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Metastasis

Interventions: Drug: Dasatinib

First Posted Date: 2006-09-04

Last Posted Date: 2011-03-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 55

Registration Number: NCT00371254

Locations: 🇺🇸
Dana-Farber Cancer Inst, Boston, Massachusetts, United States
🇺🇸
University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States
🇪🇸
Local Institution, Lleida, Spain

and more 3 locations

Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

Phase 3

Completed

Conditions: Deep Vein Thrombosis
Pulmonary Embolism

Interventions: Drug: Apixaban + Placebo
Drug: Enoxaparin + Placebo

First Posted Date: 2006-09-04

Last Posted Date: 2015-12-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 3608

Registration Number: NCT00371683

Locations: 🇺🇸
Martin Bowen Hefley Orthopedics, Little Rock, Arkansas, United States
🇺🇸
Jewett Orthopaedic Clinic, Winter Park, Florida, United States
🇺🇸
Atlanta Knee And Sports Medicine, Decatur, Georgia, United States

and more 22 locations

Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection

Phase 4

Completed

Conditions: Hepatitis B Infection

Interventions: Drug: Entecavir

First Posted Date: 2006-09-01

Last Posted Date: 2012-04-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 131

Registration Number: NCT00371150

Locations: 🇺🇸
Alabama Liver & Digestive Specialists (Alds), Montgomery, Alabama, United States
🇺🇸
University Of Arizona, Tucson, Arizona, United States
🇺🇸
Empire International Research, Miami, Florida, United States

and more 12 locations

Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Atazanavir+Ritonavir+Tenofovir
Drug: Atazanavir+Ritonavir+Tenofovir+Famotidine

First Posted Date: 2006-08-17

Last Posted Date: 2011-04-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 40

Registration Number: NCT00365339

Locations: 🇺🇸
Local Institution, Hamilton, New Jersey, United States

Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)

First Posted Date: 2006-08-16

Last Posted Date: 2014-04-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 56

Registration Number: NCT00364793

Locations: 🇹🇭
Local Institution, Bangkok, Thailand

A Study of the Alternative Administration of Ixabepilone and Vinflunine

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: vinflunine + ixabepilone

First Posted Date: 2006-08-10

Last Posted Date: 2016-09-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 60

Registration Number: NCT00362830

Locations: 🇺🇸
University Of Miami Miller School Of Medicine, Miami, Florida, United States
🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States

Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Atazanavir Sulphate
Drug: Atazanavir Sulphate + Rosiglitazone maleate
Drug: Rosiglitazone maleate
Drug: Atazanavir Sulphate + Ritonavir
Drug: Atazanavir Sulphate + Ritonavir + Rosiglitazone maleate

First Posted Date: 2006-08-10

Last Posted Date: 2011-04-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 14

Registration Number: NCT00362726

Locations: 🇺🇸
Local Institution, Hamilton, New Jersey, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy